Next Generation Cancer Vaccine Development Summit (September 7-9, Digital Event)

Memo

The 3-day program will bring together a wealth of knowledge into the once again growing field of cancer vaccines, bringing together both pioneering academics and non-profit institutions, and leading biotech and pharma. Expect to hear case studies and updates on understand immune suppression mechanisms and the tumor microenvironment, combination therapies, antigen selection, and optimizing vaccine platforms. Attend this event to:- Understand how a novel primer boost vaccine system drives tumor-specific and potent CD8+ responses for cancer immunotherapy from Gritstone Oncology - Hear Janssen speak on the critical steps in finding optimal antigens for cancer vaccinations, novel tumor bioavailability, and understanding transcriptional availability - Gain awareness with the of increasing preclinical data implicating how the timing of anti-PD-1 therapy may impact on anti-tumor immune responses generated by neoantigen vaccination with the Dana Faber Cancer Institute - Appreciate the challenges of tumor microenvironment modulation by accessing data with Targovax to combination therapies using immune checkpoint inhibitors - Hear Geneos speak on the the rationale of targeting unique antigens from individual patient tumors to design, manufacture, and deliver personalized immunotherapies Tickets https://go.evvnt.com/778973-0?pid=5569 Brochure https://go.evvnt.com/778973-3?pid=5569  Prices:Drug Developer - Conference + Workshop Day USD 2697.00,Drug Developer - Conference Only USD 1999.00,Academic / NFP - Conference + Workshop Day USD 2397.00,Academic / NFP - Conference Only USD 1799.00,Service Provider - Conference + Workshop Day USD 3297.00,Service Provider - Conference Only USD 2499.00 Speakers: Nicholas Heimann, Nicholas Pharmaceuticals, Eric Halioua, PDC*line Pharma, Niranjan Sardesai, Geneos Therapeutics, Tom Davis, Genocea Biosciences, Victor Levitsky, Targovax, Karin Jooss, Gritstone Oncology, Hans-Peter Gerber, 3T Biosciences, Jessica Flechtner, Genocea Biosciences, Laurent Humeau, Inovio, Roman Yelensky, Gritstone Oncology, Wigard Kloosterman, Frame Therapeutics, Peter Joyce, Grey Wolf Therapeutics, Michael Ciesielski, MimiVax, Agnete Fredriksen, Vaccibody, Alexandre Reuben, The University off Texas MD Anderson Cancer Center, David Reardon, Dana-Faber Cancer Institute, Eli Gilboa, University of Miami, Miller School of Medicine, Russell Pachynski, Washington University School of Medicine, Mark Findeis, Agenus Bio, Ronit Satchi-Fainaro, Tel Aviv University, Alejandro Sepulveda, Janssen, Wouter Scheper, Netherlands Cancer Institute, Christopher Rose, Genentech, Lena Kranz, BioNTech, Lelia Delamarre, Genentech, Hubert Lam, Genocea Biosciences, Helena Florindo, University of Lisbon, Vipul Bhargava, Janssen Time: On Tuesday September 07, 2021 at 9:00 am (ends Thursday September 09, 2021 at 5:00 pm)